T.C.L. Pharmaceuticals Limited
About T.C.L. Pharmaceuticals Limited
Data last updated:
T.C.L. Pharmaceuticals Limited is a public limited company based in Jaipur, Rajasthan, India. It operates in the manufacturing segment of the chemicals sector. It was incorporated on 07 October 1985 and has been in existence for over 41 years.
The company is registered with the Registrar of Companies (ROC), Jaipur, under CIN U24232RJ1985PLC003419.
The company has an authorised share capital of ₹25 Lakh and a paid-up capital of ₹9.57 Lakh. It is led by directors including Surendra Kumar Bagrecha and Narendra Jain.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Jaipur, Rajasthan.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.71 Lakh. For the same year it recorded a net profit of ₹668 (net margin 0.4%) and EBITDA of ₹668 (EBITDA margin 0.4%). Revenue has grown at a compounded annual rate (CAGR) of 327% over three years and 48% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
T.C.L. Pharmaceuticals Limited's registered office is in Jaipur, Rajasthan. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressKasara No 683/203 685/630 Hardhyanpura, Ajmer Road, Jaipur, Rajasthan, India – 303007
- IndustryChemicals, Manufacturing, Other Chemical Product
To see the full contact details of T.C.L. Pharmaceuticals Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of T.C.L. Pharmaceuticals Limited
FY 2025 filings availableT.C.L. Pharmaceuticals Limited reported revenue of ₹1.71 Lakh for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 48% over five years. EBITDA rose 100% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹668 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹668 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 0.4% | ||||
| Net Profit Margin | 0.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of T.C.L. Pharmaceuticals Limited, buy the company report.
Board of directors of T.C.L. Pharmaceuticals Limited
T.C.L. Pharmaceuticals has 4 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Surendra Kumar Bagrecha Also directs: Aryan Handicrafts Private Limited, Multivision Developer Private Limited, Murli Investment Company Private Limited and 4 more | Director | 19 Jan 2023 | 3 Years 9 Months | Current |
| Narendra Jain | Director | 19 Jan 2023 | 3 Years 9 Months | Current |
| Ashok Kumar Choraria Also directs: Dileep Crafts Private Limited, Multivision Developer Private Limited, D K Enclave Private Limited and 3 more | Director | 19 Jan 2023 | 3 Years 9 Months | Current |
| Dileep Baid | Director | 19 Jan 2023 | 3 Years 9 Months | Current |
Peer comparison
T.C.L. Pharmaceuticals Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Fairoz Deshmukh Foundation | ₹1.72 Lakh (FY 2024) | Thane, Maharashtra, India | ||||
| Neplar Pharmaceutical Private Limited | ₹1.72 Lakh (FY 2023) | -57.0% | Pinjore, Haryana, India | |||
| Xenerx Healthcare Services LLP | ₹1.71 Lakh (FY 2021) | 28859.0% | Canacona, Goa, India | |||
| Enlasia Pharmaceuticals Private Limited | ₹1.71 Lakh (FY 2023) | 139.0% | Gurugram, Haryana, India | |||
| Alphonce Pharmaceuticals Private Limited | ₹1.71 Lakh (FY 2023) | Patna, Bihar, India | ||||
| T.C.L. Pharmaceuticals Limitedthis company | ₹1.71 Lakh (FY 2025) | ₹668 | 0.4% | Jaipur, Rajasthan, India | ||
| Sri Rajeshwara Farms Private Limited | ₹1.7 Lakh (FY 2024) | 6.0% | Hyderabad, Telangana, India | |||
| Rivoma Pharmaceuticals Private Limited | ₹1.7 Lakh (FY 2025) | -62.0% | Chandrapur, Maharashtra, India | |||
| Doctor Choice Pharmaceuticals Private Limited | ₹1.69 Lakh (FY 2025) | -58.0% | Faridabad, Haryana, India | |||
| Raquel Pharmaceuticals Private Limited | ₹1.69 Lakh (FY 2020) | -88.0% | Vadodara, Gujarat, India | |||
| Arcorp Pharmaceuticals Private Limited | ₹1.69 Lakh (FY 2024) | -98.0% | Bhopal, Madhya Pradesh, India |
To see the full peer comparison of T.C.L. Pharmaceuticals Limited, buy the company report.
Auditor
T.C.L. Pharmaceuticals Limited is audited by PAREKH & CO for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| PAREKH & CO | FY 2017 | 106574 |
Shareholding
The shareholding of T.C.L. Pharmaceuticals Limited is on record for 3 financial years, the latest being FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of T.C.L. Pharmaceuticals Limited, buy the company report.
Legal cases
No court or tribunal cases involving T.C.L. Pharmaceuticals Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for T.C.L. Pharmaceuticals Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for T.C.L. Pharmaceuticals Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
T.C.L. Pharmaceuticals Limited has 12 board changes on record since 1985: 8 appointments and 4 cessations. The latest: Veer Vinodkumar Dadhia ceased to be Director on 30 Mar 2023.
3 earlier events are in the company report.
Frequently asked questions
T.C.L. Pharmaceuticals is an active public limited company based in Jaipur, Rajasthan, India. The company works in manufacturing, within the chemicals industry. It was incorporated on 07 October 1985 (41+ years old) and is registered under CIN U24232RJ1985PLC003419.
T.C.L. Pharmaceuticals has 4 current directors:
- Surendra Kumar Bagrecha - Director
- Narendra Jain - Director
- Ashok Kumar Choraria - Director
- Dileep Baid - Director
The latest financial statements of T.C.L. Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of T.C.L. Pharmaceuticals is U24232RJ1985PLC003419. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
T.C.L. Pharmaceuticals was incorporated on 07 October 1985, making it 41+ years old. It is registered with the Registrar of Companies, Jaipur.
The peers of T.C.L. Pharmaceuticals by revenue are Fairoz Deshmukh Foundation, Neplar Pharmaceutical Private Limited, Xenerx Healthcare Services LLP, Enlasia Pharmaceuticals Private Limited, Alphonce Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals).
Veer Vinodkumar Dadhia ceased to be Director on 30 Mar 2023. Harsh Vinod Dadhia ceased to be Director on 01 Feb 2023. Sheetal Vinod Dadhia ceased to be Director on 01 Feb 2023. T.C.L. Pharmaceuticals has 12 board changes on record in total.
The registered office of T.C.L. Pharmaceuticals is at Kasara No 683203 685630 Hardhyanpura, Ajmer Road, Jaipur, Rajasthan, India – 303007.
T.C.L. Pharmaceuticals operates in the chemicals industry, in the manufacturing segment.
The compliance status of T.C.L. Pharmaceuticals is compliant as of 09 August 2026. The company is actively filing with the Registrar of Companies.
T.C.L. Pharmaceuticals can be reached at its registered office: Kasara No 683203 685630 Hardhyanpura, Ajmer Road, Jaipur, Rajasthan, India – 303007.